(MedPage Today) — But with a veto waiting in the wings, is this a pyrrhic victory?
Category: News
Obamacare and Planned Parenthood Get Axed by Senate
(MedPage Today) — But with a veto waiting in the wings, is this a pyrrhic victory?
CMS: 2014 Saw Spike in Healthcare Spending
(MedPage Today) — Growth attributed to coverage expansion under ACA and new hep C drugs
rhNGF, der biotechnologisch hergestellte Wirkstoff von Dompé gegen neurotrophe Keratopathie, erhält Orphan-Drug-Status von der Europäischen Arzneimittel-Agentur (EMA)
MAILAND–(BUSINESS WIRE)–Der rekombinante humane Nervenwachstumsfaktor (rhNGF) erhält vom „Ausschuss für Arzneimittel für seltene Leiden“ der Europäischen Arzneimittel-Agentur (EMA) den Orphan-Drug-Status bei der Behandlung der neurotrophen Keratopathie. Das von Dompé entwickelte und biotechnologisch hergestellte Molekül basiert auf den Forschungen der Nobelpreisträgerin Rita Levi Montalcini. NGF ist der erste neurotrophe Faktor, der identifiziert und isoliert werden konnte. Er zählt zu den in
rhNGF, la molécula de biotecnología de Dompé para el tratamiento de la queratitis neurotrófica, recibe la designación de medicamento huérfano de la Agencia Europea de Medicamentos
MILÁN–(BUSINESS WIRE)–La empresa biofarmacéutica Dompé ha anunciado hoy que el Comité de Medicamentos Huérfanos de la Agencia Europea de Medicamentos ha designado oficialmente el factor de crecimiento nervioso humano recombinante (rhNFG) – la molécula de biotecnología en investigación desarrollada por Dompé de acuerdo con los estudios de la premio Nobel Rita Levi-Montalcini – como medicamento huérfano para el tratamiento de la queratitis neurotrófica. NGF es el primer factor neurotrófico que
rhNGF, la molécule de Dompé Biotech pour le traitement de la kératite neurotrophique, obtient la désignation de médicament orphelin de l’Agence européenne du Médicament
MILAN–(BUSINESS WIRE)–La société biopharmaceutique Dompé a annoncé aujourd’hui que le Comité des Médicaments orphelin de l’Agence européenne du Médicament (EMA) a désigné officiellement le facteur de croissance du nerf humain recombinant (rhNGF) – la molécule biotechnologique expérimentale développée par Dompé sur la base des recherches effectuées par la lauréate du Prix Nobel Rita Levi Montalcini – comme étant un médicament orphelin pour le traitement de la kératite neurotrophique. Le facteu
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies for diseases of the eye, announces completion of $20 million Series C financing.
Readers Name Biggest Medical Stories of 2015
The debut of the ICD-10 diagnostic codes topped the list, followed by California’s approval of physician-assisted suicide. The end of the 10-year MOC exam ranked as the most exciting piece of news. Medscape Medical News
rhNGF, the Dompé Biotech Molecule for the Treatment of Neurotrophic Keratitis, Receives Orphan Drug Designation from the European Medicines Agency
MILAN–(BUSINESS WIRE)–The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) – the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini – as an orphan drug for the treatment of neurotrophic keratitis. NGF is the first neurotrophic factor to be identified and purified, and represents
rhNGF, la molecola biotecnologica Dompé per la cura della cheratite neurotrofica, designato farmaco orfano dalla European Medicines Agency
MILANO–(BUSINESS WIRE)–L’azienda biofarmaceutica Dompé annuncia che il Comitato per i Farmaci Orfani dell’EMA (European Medicines Agency) ha ufficialmente designato rhNGF, la molecola biotecnologica sperimentale messa a punto dalla ricerca Dompé sulla scorta degli studi del Premio Nobel per la Medicina Rita Levi Montalcini, come farmaco orfano per il trattamento della cheratite neurotrofica. NGF (Nerve Growth Factor) è il primo fattore neurotrofico a essere identificato e purificato e, oggi,
Doc Groups Urge Congress to Drop Gun Research Ban
(MedPage Today) — Let the CDC do research on firearm violence, they say
Ptosis and Diplopia in a 74-Year-Old With History of Stroke
Five years after her initial hospitalization, a patient returns with ptosis and diplopia. Are these a sign that another stroke has occurred, or is a different diagnosis called for? Medscape Ophthalmology
CoreSource and Liazon Partner to Launch TPA Private Exchange Solution
LAKE FOREST, Ill.–(BUSINESS WIRE)–CoreSource, a national health benefits administrator, & Liazon, operator of industry-leading private benefits exchange Bright Choices®, creates a new third-party administrator (TPA) private exchange.
Ophthotech Corporation to Present at the Oppenheimer 26th Annual Healthcare Conference
NEW YORK–(BUSINESS WIRE)–Ophthotech announced today that David R. Guyer will present an overview of the Company at the Oppenheimer 26th Annual Healthcare Conference in New York City on December 8, 2015 at 8:35 a.m. ET.
Website launched with the aim of raising awareness of Dry Eye Syndrome and related co-morbidities
“Studies have shown that 98-99% of patients want information about their options,” said co-founder, chair, and executive director Natalia Warren.
HHS: Dramatic Downturn in Hospital-Acquired Conditions
(MedPage Today) — Big reductions in adverse drug events, pressure ulcers
Researchers grow retinal nerve cells in the lab
Work could eventually lead to cell transplants for people blinded by glaucoma, MS.
Morning Break: Cuba’s Doc Drain; Harvard Eases COI Rules; ‘Most Virile Man’
(MedPage Today) — Health news and commentary from around the Web, gathered by the MedPage Today
Johns Hopkins researchers develop method to turn stem cells into retinal ganglion cells
Johns Hopkins researchers have developed a method to efficiently turn human stem cells into retinal ganglion cells, the type of nerve cells located within the retina that transmit visual signals from the eye to the brain. Death and dysfunction of these…
Diabetic Vision Loss Medication May Promote Return to Driving
After a year of treatment with the drug ranibizumab (Lucentis), some people with vision loss due to diabetes regain their confidence to drive and have vision good enough to do so, according to a new study. Reuters Health Information